Conference Call and Webcast to Follow CONCORD, Calif.--(BUSINESS WIRE)--Feb. 8, 2007--Cerus Corporation
(NASDAQ:CERS) announced today that its fourth quarter and year end
2006 financial results will be released on Thursday, February 22,
2007, after the close of the market and will host a conference call
and live webcast at 4:30 p.m EST that afternoon. Management will
discuss the company's fourth quarter and year end 2006 results,
provide an overview of the company, and guidance for 2007. To access the webcast via the internet, log on to www.cerus.com.
Please connect to the company's website at least 15 minutes prior to
the conference call to ensure adequate time for any software
downloads. Alternatively, you may access the live conference call by
dialing 866-383-8108 (U.S.) or 617-597-5343 (International) and dial
participant passcode 27219354. A telephone replay will be available
approximately two hours after the call through 5:00 p.m. EST, February
27, 2007. To access the replay, please call 888-286-8010 (U.S.) or
617-801-6888 and enter passcode 65485120. The webcast will be archived
on www.cerus.com through March 22, 2007. ABOUT CERUS Cerus Corporation is a biopharmaceutical company that develops and
commercializes novel, proprietary products in the fields of blood
safety and immunotherapy to provide safer, more effective medical
options to patients in areas of substantial unmet medical needs. In
the field of blood safety, the company is developing and
commercializing the INTERCEPT Blood System, which is based on the
company's proprietary Helinx technology and is designed to enhance the
safety of donated blood components by inactivating viruses, bacteria,
parasites and other pathogens, as well as potentially harmful white
blood cells. In the field of immunotherapy, the company is employing
its proprietary attenuated Listeria vaccine platform to develop a
series of novel therapies to treat cancer, and it is applying its
proprietary Killed But Metabolically Active technology platform in
research and development of prophylactic and therapeutic vaccines for
infectious diseases. INTERCEPT, INTERCEPT Blood System and Helinx are
trademarks of Cerus Corporation.
CONTACT: Cerus Corporation
Myesha Edwards, 925-288-6017
Corporate Communications & Investor Relations SOURCE: Cerus Corporation
|